Secondary Logo

Journal Logo

LARSON DALE M. MD; COPELAND, LARRY J. MD; GALLAGER, H. STEPHEN MD; WHARTON, J. TAYLOR MD; GERSHENSON, DAVID M. MD; RUTLEDGE, FELIX N. MD
Obstetrics & Gynecology: December 1987
ORIGINAL ARTICLE: PDF Only
Free

The prognostic significance of residual endometrial carcinoma in the hysterectomy specimen after preoperative radiotherapy is controversial. Sixty-two patients with stage II endometrial carcinoma were treated with a standardized program of preoperative radiotherapy, followed in six weeks by an extrafascial hysterectomy. Twenty patients (32%) had no residual carcinoma in their hysterectomy specimens and 42 (68%) had residual carcinoma. There were no significant clinical, surgical, or pathologic differences between patients with or without residual carcinoma. Patients with no residual carcinoma had a 25% recurrence rate and a 53% actuarial five-year survival rate. Patients with residual carcinoma had a 21% recurrence rate and a 78% actuarial five-year survival rate. The presence of residual endometrial carcinoma in the hysterectomy specimen does not imply a compromised prognosis in patients with stage II endometrial carcinoma treated by the described method.

© 1987 The American College of Obstetricians and Gynecologists